Breast Cancer
Conference Coverage
Breast cancer in men comparable with women, gonadal therapy debated
MUNICH – Data from a large retrospective study of metastatic breast cancer indicates that, in general, men and women received similar treatments...
Conference Coverage
SOLAR-1 shines light on PI3K in breast cancer
MUNICH – The selective PI3K inhibitor added to fulvestrant extended progression-free survival in breast cancer patients with PIK3CA mutations.
News
ICYMI: Hereditary cancer screening feasible in community gynecologic practices
Conference Coverage
HDAC/aromatase inhibitor combo shows promise for HR+/HER2- advanced breast cancer
MUNICH – Chidamide + exemestane combination therapy increased PFS by about 4 months, compared with exemestane...
Conference Coverage
PALOMA-3: Overall survival better for endocrine-sensitive patients only
MUNICH –
Conference Coverage
Finally, immunotherapy shows benefit in TNBC
MUNICH – Adding atezolizumab to nab-paclitaxel improved progression-free and overall survival in patients with PD-L1 positive triple-negative...
Conference Coverage
Genotype-driven dosing reduces 5-FU, capecitabine toxicity
MUNICH – Clinic-based screening for four common variants and dose-adapted therapy reduced severe fluoropyrimidine-associated toxicity.
News
Talazoparib approved for HER2-negative advanced breast cancer
The
Audio
New and promising GSM treatments, more clinical takeaways from NAMS 2018
Dr. Richard-Davis served as the Scientific Program Chair of the 2018 NAMS Meeting. In this audiocast she highlights several clinical takeaways...
News
Tech-based cancer company raises access concerns
Oncologists say a new company that aims to link patients with cancer care and clinical trials through technology has both positives and negatives...